Sanjivani Paranteral Ltd vs Sms Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 16, 2026

Key Highlights

The Latest Trading Price of Sanjivani Paranteral Ltd is ₹ 136.3 as of 15 May 15:30 . The P/E Ratio of Sanjivani Paranteral Ltd changed from 28.4 on March 2024 to 0 on March 2023 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of SMS Pharmaceuticals Ltd changed from 30.2 on March 2024 to 0 on March 2023 . This represents a CAGR of -100.00% over 5 years The Market Cap of Sanjivani Paranteral Ltd changed from ₹ 175.32 crore on March 2024 to ₹ 0 crore on March 2023 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of SMS Pharmaceuticals Ltd changed from ₹ 1507 crore on March 2024 to ₹ 489.29 crore on March 2023 . This represents a CAGR of -20.15% over 5 years The revenue of Sanjivani Paranteral Ltd for the Mar '26 is ₹ 13.81 crore as compare to the Dec '25 revenue of ₹ 22.36 crore. This represent the decline of -38.24% The revenue of SMS Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 214.2 crore. This represent the decline of -100% The ebitda of Sanjivani Paranteral Ltd for the Mar '26 is ₹ 2.17 crore as compare to the Dec '25 ebitda of ₹ 4.13 crore. This represent the decline of -47.46% The ebitda of SMS Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 47.4 crore. This represent the decline of -100% The net profit of Sanjivani Paranteral Ltd changed from ₹ 1.71 crore to ₹ 0.55 crore over 8 quarters. This represents a CAGR of -43.29% The net profit of SMS Pharmaceuticals Ltd changed from ₹ 16.37 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Sanjivani Paranteral Ltd changed from 7.33 % on March 2025 to 7.33 % on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Dividend Payout of SMS Pharmaceuticals Ltd changed from 4.17 % on March 2021 to 5.19 % on March 2025 . This represents a CAGR of 4.47% over 5 years .

About Sanjivani Paranteral Ltd

Sanjivani Paranteral Limited is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades.
The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun. Incorporated as a Public Limited Company in October, 1994, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry.
The Company is involved in the manufacturing of pharmaceutical medicines.
Its products includes oral solids, small volume parenteral and sterile powder formulations. The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative.

About SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Limited was incorporated in December, 1987.
The company is engaged in the business of manufacturing of Active Pharma Ingredients and their intermediates.
Apart from R &D Center at Gagillapur, Hyderabad, the company is having manufacturing facilities at Bachupally, Hyderabad and also at Kandivalasa Village in Vijayanagaram District of Andhra Pradesh. During the year 2015, the company has re-enforced its fundamental strength of FDA compliant facilities by successfully completing the US FDA audits at Kandivalasa and Bachupally facilities. During the year 2015, the company filed 9 Drug Master Files and total DMFs filed up to 31 March 2015 are 24. During the year 2014-15, the Company acquired 12,25,900 equity shares of Rs. 10/- each in M/s.
VKT Pharma Private Limited.

FAQs for the comparison of Sanjivani Paranteral Ltd and SMS Pharmaceuticals Ltd

Which company has a larger market capitalization, Sanjivani Paranteral Ltd or SMS Pharmaceuticals Ltd?

Market cap of Sanjivani Paranteral Ltd is 167 Cr while Market cap of SMS Pharmaceuticals Ltd is 3,747 Cr

What are the key factors driving the stock performance of Sanjivani Paranteral Ltd and SMS Pharmaceuticals Ltd?

The stock performance of Sanjivani Paranteral Ltd and SMS Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanjivani Paranteral Ltd and SMS Pharmaceuticals Ltd?

As of May 16, 2026, the Sanjivani Paranteral Ltd stock price is INR ₹136.3. On the other hand, SMS Pharmaceuticals Ltd stock price is INR ₹400.2.

How do dividend payouts of Sanjivani Paranteral Ltd and SMS Pharmaceuticals Ltd compare?

To compare the dividend payouts of Sanjivani Paranteral Ltd and SMS Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.